Abstract
Recent evidence highlights the efficacy of mavacamten in reducing left ventricular outflow tract (LVOT) gradients in patients with hypertrophic cardiomyopathy (HCM), which is illustrated in this case. Additionally, the potential of magnetocardiography (MCG) as a novel, objective diagnostic and monitoring tool for nonischemic cardiomyopathies is demonstrated.